Congressional collaboration on DTC device ads
This article was originally published in The Gray Sheet
Sen. Herb Kohl, D-Wis., wants to work with Rep. Bart Stupak, D-Mich., on addressing direct-to-consumer medical device advertisements, "to determine if moratoriums or other proposed restrictions" might be necessary for ads for restricted devices, the Senator writes in a Sept. 26 letter to Stupak, who is chairman of the House Energy and Commerce Committee's oversight sub-panel. Kohl notes that Stupak and Rep. John Dingell, D-Mich., chairman of the House Energy Committee, have asked drug firms to consider a two-year moratorium on DTC ads for new prescription drugs, as recommended by the Institute of Medicine. Kohl held a hearing Sept. 17 on DTC ads for devices ("1The Gray Sheet" Sept. 22, 2008, p. 3)
You may also be interested in...
Senate Special Committee on Aging Chairman Herb Kohl, D-Wis., is considering legislation to restrict direct-to-consumer advertising of medical devices
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.